Guidelines for Anticoagulation Therapy for Secondary Prevention After Deep Vein Thrombosis
Click CC to turn on closed captioning.
An estimated 37 million patients are affected by thrombotic disorders each year. This number will continue to rise with the increase in our aging population. Dr. McBane will describe laboratory testing for thrombophilia and current guidelines for anticoagulation therapy following deep vein thrombosis and pulmonary embolism. We invite you to join us at the Clinical and Laboratory Update in Thrombosis and Anticoagulation conference August 4-5, 2011 to learn more about the evaluation and treatment of patients with arterial and venous thrombotic disorders.
- Robert McBane, MD of the Division of Hematopathology
- Thrombophilia Profile
- D-Dimer, Plasma
- Antithrombin Activity, Plasma
- Protein S Activity, Plasma
- Protein S Antigen, Plasma
- Protein C Activity, Plasma
- Protein C Antigen, Plasma
- Activated Protein C Resistance V (APCRV), Plasma
- Factor V Leiden (R506Q) Mutation, Blood
- Prothrombin G20210A Mutation, Blood
- Warfarin Sensitivity Genotype by Sequence Analysis, Blood
Forward to a Colleague
Share this presentation with:
If you have questions, email .